Skip to main content
Download PDF
Download ePub
  • Research article
  • Open access
  • Published:

Upregulation of brain-derived neurotrophic factor by Shiikuwasha (Citrus depressa Hayata)

Journal of Pharmaceutical Health Care and Sciences volume 9, Article number: 40 (2023) Cite this article

Abstract

Background

A reduction in the brain-derived neurotrophic factor (BDNF) level in the brain causes depression, whereas an increase in its level has therapeutic benefits against depression. BDNF is synthesized in various peripheral tissues and transported to the brain via the peripheral circulation across the blood–brain barrier. Therefore, substances that upregulate peripheral BDNF level may be used to prevent and treat depression. Previously, we demonstrated that Citrus unshiu peel (Chinpi) and C. natsudaidai increased BDNF level in a human renal adenocarcinoma cell line ACHN, which has BDNF-producing ability. Here, we evaluated whether Shiikuwasha (C. depressa Hayata), a citrus species cultivated in East Asia, can upregulate BDNF level in ACHN cells.

Methods

We evaluated the effects of test samples on BDNF production by measuring BDNF level in the medium of ACHN cells after a 24 h cultivation in the presence of test samples. The BDNF mRNA level was measured by quantitative reverse transcription-polymerase chain reaction, and the phosphorylation level of cyclic adenosine monophosphate response element-binding protein (CREB), a transcription factor regulating BDNF expression, was determined using Western blotting.

Results

We found that methanol extracts of Shiikuwasha peel, pulp, and seed increased the BDNF level in the culture medium of ACHN cells. Shiikuwasha peel and pulp extracts also upregulated BDNF mRNA level and phosphorylation of CREB.

Conclusions

These results suggest that Shiikuwasha includes the candidate antidepressant substances with peripheral BDNF-upregulation effect.

Background

Depression is a common mental disorder characterized by low mood, loss of interest, anhedonia, sleep disturbance, and suicidal tendencies and negatively affects human well-being and socio-economic aspects [1, 2]. Currently, clinically available antidepressants, such as selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, and tricyclic and tetracyclic antidepressants, are based on the hypothesis that monoamine deficiency in the brain causes depression. However, these drugs are ineffective in approximately 30% of patients with depression [3] and take several weeks to elicit an antidepressant effect [4]. Additionally, there are no effective prophylactic strategies against depression. Therefore, novel therapeutic and prophylactic approaches for depression are necessary.

Brain-derived neurotrophic factor (BDNF), first isolated from a pig brain in 1982 [5], is a critical neurotrophin for neurogenesis, neuronal differentiation, neuroprotection, and synaptic plasticity in the central nervous system (CNS) [6, 7]. BDNF is a 14-kDa protein composed of 119 amino acids. BDNF transcription is regulated by the cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB) signaling pathway [8, 9]. CREB is activated by phosphorylation at Ser-133 [10]. CREB phosphorylation is regulated by the activation of various signaling pathways, including phosphoinositide 3-kinase/protein kinase B (Akt), cAMP-dependent protein kinase (PKA), calcium/calmodulin-dependent protein kinase, and Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase [9, 11, 12].

Reduction in BDNF level in the hippocampus is reportedly associated with depression [13, 14], and the BDNF level is reduced in the postmortem brains of patients with depression [15]. Moreover, the BDNF level in the hippocampus is reduced by various stresses such as chronic unpredictable mild stress, restraint stress, corticosterone injection, olfactory bulbectomy, and maternal stress in rodents [16,17,18,19,20], and BDNF administration to the hippocampus elicits antidepressant-like effects in rats [21, 22]. These results support the neurotrophic hypothesis of depression, that is, BDNF is a crucial factor in depression development [14]. Hence, BDNF upregulation in the brain is considered beneficial for preventing and treating depression.

BDNF is expressed in the CNS and is present in nearly all regions of the brain [23, 24], especially in the hippocampus and cerebral cortex. Additionally, BDNF is produced in the skeletal muscles, kidney, thymus, heart, liver, lung, and spleen [25,26,27,28,29,30]. It can be transported to the brain from the peripheral circulation by crossing the blood–brain barrier [31, 32]. Furthermore, a positive correlation exists between BDNF level in the brain and that in the blood [33], and peripheral BDNF administration exerts an antidepressant-like effect and upregulates BDNF level in the hippocampus [34]. Therefore, compounds that elevate BDNF level in the peripheral circulation potentially exhibit prophylactic and therapeutic effects against depression due to an increase in the level of BDNF transported to the brain.

In our previous study, we demonstrated that the human renal adenocarcinoma cell line ACHN produces and secretes BDNF. Using the cell line, we screened for substances that upregulate BDNF level to identify prophylactic and therapeutic agents against depression [35]. We demonstrated that foxtail millet, some Kampo medicines (Japanese traditional medicines), such as Chotosan, Hochuekkito, Kososan, and Ninjinyoeito, and Citrus unshiu peel (crude drug; Chinpi), an ingredient of these four Kampo medicines, significantly increase BDNF level in the culture medium of ACHN cells [36, 37]. Moreover, we reported that Citrus natsudaidai upregulates BDNF protein and mRNA level in ACHN cells [38]. As treatment with C. unshiu and C. natsudaidai increased the BDNF level in the culture medium of ACHN cells [36, 38], Citrus species are thought to enhance BDNF production in ACHN cells.

Shiikuwasha (Citrus depressa Hayata) is a well-known Citrus species that grows natively in Taiwan, Korea, and Japan (Okinawa) [39]. Approximately 3.0 × 106 kg of Shiikuwasha is produced each year in Okinawa and is used as a fresh fruit as well as for making juice, food additives, and functional foods. Shiikuwasha extract has anti-obesity effects and alleviates skeletal muscle atrophy and osteoarthritis progression [40, 41], however, it is unknown whether Shiikuwasha affects BDNF production. The aim of this study was to evaluate the effect of Shiikuwasha on BDNF level in ACHN cells.

Methods

Reagents and materials

Shiikuwasha (Citrus depressa Hayata) was supplied by the Division of Citrus Research, Institute of Fruit Tree and Tea Science, National Agriculture and Food Research Organization (NARO) (Shizuoka, Japan). They were harvested at NARO's farm on December 2, 2021. Botanical classification was conducted by NARO and Dr. Kensuke Nakajima. Voucher specimen of this plant (NO-Shii-001) is deposited at the Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University (Nagasaki, Japan). The Quantikine® human BDNF Immunoassay kit (Catalog # DBD00) was purchased from R&D Systems (Minneapolis, MN, USA). Dulbecco’s modified Eagle’s medium (DMEM) and TRIzol were purchased from Life Technologies (Carlsbad, CA, USA), and ReverTra Ace was purchased from Toyobo (Osaka, Japan). TB Green Fast qPCR Mix was purchased from Takara Bio. Inc. (Shiga, Japan). The primers were obtained from GeneNet (Fukuoka, Japan) or FASMAC (Kanagawa, Japan). Antibody for CREB and pCREB (Ser-133), and RIPA lysis buffer were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-β-actin antibody was obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). Hesperidin and nobiletin were purchased from Tokyo Chemical Industry Co. (Tokyo, Japan). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), and other reagents were purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan).

Cell culture

Human renal adenocarcinoma ACHN cells were cultured in DMEM supplemented with 10% fetal bovine serum at 37 °C in a humidified atmosphere with 5% CO2.

Preparation of Shiikuwasha extracts

Shiikuwasha was separated into peel (albedo and flavedo), pulp, and seeds. The peel and pulp were lyophilized using a freeze drier (FDU-1200, EYELA, Tokyo, Japan). The seeds were dried at room temperature for 48 h. Lyophilized peel and pulp, and dried seeds were crushed using a Tube Mill 100 control (IKA, Staufen, Germany). The crushed samples (5 g) were agitated in methanol for 12 h at 25 ± 2 °C. The supernatant was collected after centrifugation at 15,000 × g for 5 min and dried by spraying with nitrogen gas. Each residue was dissolved in DMSO at a final concentration of 40 mg/mL.

MTT assay

An MTT assay was performed as described previously [36]. Briefly, the cells were seeded in 96-well plates at a density of 1 × 104 cells/well and cultured for 24 h. Shiikuwasha extracts (0–100 μg/mL) were added to the culture medium. After 24 h of culture, MTT (200 μg/mL) was added to each well, and the cells were cultured for another 4 h. After removing the culture medium, formazan crystals were dissolved in DMSO. The optical density of the samples was measured at 570 nm using a Multiskan FC microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). The values were expressed as the ratio of the optical density of test extracts-treated cells to that of the control cells.

Measurement of BDNF level in the culture medium of ACHN cells

ACHN cells were seeded in 96-well plates at a density of 1 × 104 cells/well and cultured for 24 h in DMEM. Fresh DMEM with or without Shiikuwasha extracts was added to each well, and the cells were cultured for 24 h. Thereafter, the culture medium was collected, and the level of BDNF in the culture medium was measured using the Quantikine® human BDNF Immunoassay kit, according to the manufacturer’s instructions.

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

The total RNA was extracted from ACHN cells treated with or without the test samples using TRIzol reagent and reverse-transcribed to complementary DNA (cDNA) using ReverTra Ace. The reaction mixture, containing 10 μL of 2 × TB Green Fast qPCR Mix, 0.8 pmol of sense and antisense primers, and 2 μL of diluted cDNA, was loaded into a 96-well plate. PCR amplification was conducted under the following conditions: 95 °C for 30 s, followed by 40 cycles at 95 °C for 5 s and 60 °C for 10 s. PCR was performed using the CFX Connect Real-Time System (Bio-Rad, Hercules, CA, USA). The following sense and antisense primers were used: human BDNF, forward 5′-TTTGGTTGCATGAAGGCTGC-3′ and reverse 5′-GCCGAACTTTCTGGTCCTCA-3′; 18S ribosomal RNA, forward 5′-GTAACCCGTTGAACCCCATT-3′ and reverse 5′-CCATCCAATCGGTAGTAGCG-3′. Transcript levels were estimated from the respective standard curves and normalized to 18S ribosomal RNA expression (internal control).

Western blotting

ACHN cells were seeded in 6-cm dishes at a density of 0.8 × 106 cells/dish. Twenty-four hours later, the cells were treated with methanol extracts of Shiikuwasha peel and pulp (50 and 100 μg/mL) for 24 h, after which they were harvested and lysed in RIPA lysis buffer containing protease and phosphatase inhibitors. The samples were centrifuged at 12,000 × g for 15 min at 4 °C, and the protein content of the samples was determined using a dye-binding protein assay kit according to the manufacturer’s instructions (Bio-Rad). Equal amounts of proteins were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis, transferred onto polyvinylidene fluoride membranes, and detected following the method reported by Uto et al. [42].

HPLC analysis

The HPLC system was performed on a JASCO LC-2000 Plus series (JASCO, Tokyo, Japan). TSKgel ODS-100V column (4.6 × 250 mm, particle size 5 µm, Tosoh Corp. Tokyo, Japan) was used for HPLC analyses at 40 °C. The mobile phases 0.1% formic acid in acetonitrile and 0.1% formic acid in water eluted according to the following gradient program: 0–20 min (10:90 → 100:0, v/v) → 20–30 min (100:0, v/v) → 30–40 min (10:90, v/v). The flow rate was 1 mL/min, the injection volume was 10.0 µL, and the detection wavelength was 275 nm.

Sample and standard solutions were prepared by dissolving each DMSO solution in methanol followed by HPLC analysis. For the sample solutions, 40 mg/mL of the Shiikuwasha extracts (peel, pulp, and seeds) were diluted to a final concentration of 4.0 mg/mL. Hesperidin and nobiletin were used as standards. Hesperidin (50 µmol/L) and nobiletin (25 µmol/L), both diluted to 25 nmol/L separately, were used as standard solutions, and their peaks were obtained at 9.5 and 16.4 min, respectively.

Statistical analysis

Values are presented as mean ± standard deviation. Differences between the groups were analyzed using the one-way analysis of variance, followed by Dunnett's test. Differences were considered significant at P < 0.05.

Results

Effect of the methanol extracts of Shiikuwasha on BDNF level in ACHN cells

If the number of ACHN cells is substantially increased with the Shiikuwasha treatment, then the level of BDNF in the culture medium will also increase regardless of the ability of ACHN cells to produce BDNF. There was no significant increase in the viability of ACHN cells treated with Shiikuwasha extract at 50 and 100 µg/mL compared with that of the control, as determined using the MTT assay (data not shown). Therefore, we investigated the effect on BDNF level in ACHN cells using 50 and 100 µg/mL of each Shiikuwasha extract.

Shiikuwasha peel extracts significantly increased the BDNF level in the culture medium, 2.08-fold increase (484.4 pg/mL) upon treatment with 50 μg/mL extract and 2.20-fold increase (513.9 pg/mL) upon treatment with 100 μg/mL extract, compared with that of the control (233.1 pg/mL) (Fig. 1). Shiikuwasha pulp extracts significantly increased the BDNF level in the culture medium, 1.60-fold increase (372.5 pg/mL) at 50 μg/mL and 2.05-fold increase (478.0 pg/mL) at 100 μg/mL, compared with that of the control (233.1 pg/mL) (Fig. 1). Furthermore, Shiikuwasha seed extracts significantly upregulated the BDNF level, 1.28-fold increase (298.3 pg/mL) at 50 μg/mL and 1.26-fold increase (292.7 pg/mL) at 100 μg/mL, compared with that of the control (233.1 pg/mL) (Fig. 1). The BDNF concentration in the culture medium treated with Chinpi (100 μg/mL; positive control), which was found to upregulate BDNF previously [36], was 429.1 pg/mL (Fig. 1).

Fig. 1
figure 1

Effects of Shiikuwasha extracts on brain-derived neurotrophic factor (BDNF) level in ACHN cell culture medium. ACHN cells were cultured for 24 h with the methanol extracts of Shiikuwasha peel, pulp, and seeds at 50 and 100 µg/mL. BDNF level was measured using the enzyme-linked immunosorbent assay. Each value represents BDNF level in the culture medium. ACHN cells treated with Chinpi were used as the positive control. Data are expressed as mean ± SD (controls; n = 4, other groups; n = 3). Dunnett's test; *P < 0.05 vs. control (0 µg/mL)

Full size image

Effects of Shiikuwasha extracts on BDNF mRNA level in ACHN cells

As Shiikuwasha peel and pulp methanol extracts strongly upregulated the BDNF level in ACHN cells, we further evaluated BDNF expression in ACHN cells treated with Shiikuwasha peel and pulp extracts using qRT-PCR. BDNF expression in ACHN cells treated with peel extract increased by 1.8-fold at 50 μg/mL and 2.7-fold at 100 μg/mL compared with that of the control (Fig. 2). In cells treated with pulp extract, BDNF expression increased by 2.2-fold at 50 μg/mL and 1.7-fold at 100 μg/mL compared with that in the control cells (Fig. 2).

Fig. 2
figure 2

Effects of methanol extracts of Shiikuwasha peel or pulp on BDNF level in ACHN cells. ACHN cells were cultured for 24 h with each extract. BDNF level was measured using quantitative reverse transcription-polymerase chain reaction. Each value represents BDNF level of treated cells relative to that of the control (0 µg/mL). Data are expressed as mean ± SD (peel at 50 µg/mL; n = 3, other groups; n = 4). Dunnett's test; *P < 0.05 vs. control (0 µg/mL)

Full size image

Effects of Shiikuwasha extracts on CREB phosphorylation in ACHN cells

BDNF transcription is regulated by phosphorylated CREB [8, 9]. As an increase in BDNF transcription by Shiikuwasha extracts was observed, we examined whether Shiikuwasha extracts affect CREB phosphorylation. Phosphorylated CREB expression in ACHN cells treated with Shiikuwasha peel and pulp extracts was higher than that of the control (Fig. 3).

Fig. 3
figure 3

Effects of methanol extracts of Shiikuwasha peel or pulp on CREB phosphorylation in ACHN cells. ACHN cells were cultured for 24 h with the methanol extracts of Shiikuwasha peel and pulp at 50 and 100 µg/mL. CREB and pCREB expression was evaluated using Western blotting

Full size image

HPLC analysis of Shiikuwasha extracts

Shiikuwasha is particularly rich in flavonoids such as hesperidin and nobiletin (Fig. 4A) [43]. Hesperidin and nobiletin are reportedly present in higher concentrations in the Shiikuwasha peel than in the pulp [43]. To confirm that Shiikuwasha contains these compounds, each Shiikuwasha extract was subjected to HPLC analysis. Hesperidin was identified in all extracts by its peak at 9.5 min, corresponding to the retention time of the compound (Fig. 4B). Furthermore, the observed peak areas suggested higher content in the peel, pulp, and seed, in that order (Fig. 4C). Nobiletin was only identified in the peel extract by its peak at 16.4 min, corresponding to the retention time of the compound (Fig. 4B).

Fig. 4
figure 4

A Chemical structures of hesperidin and nobiletin. B HPLC chromatograms of Shiikuwasha extracts (peel, pulp, and seeds: 4.0 mg/mL) and standard solution (hesperidin and nobiletin: 25 nmol/L). Retention times of hesperidin and nobiletin were 9.5 and 16.4 min, respectively. C Peak areas of hesperidin and nobiletin from Shiikuwasha extracts

Full size image

Discussion

Based on the neurotrophic hypothesis of depression proposed by Duman et al. [14] and Duman and Monteggia [13], upregulation of BDNF level in the brain region can serve as an efficient prophylactic and therapeutic strategy against depression. Considering that BDNF crosses the blood–brain barrier [31] and BDNF administration peripherally induces an increase in BDNF level in the hippocampus [34], upregulation of peripheral BDNF level could increase brain BDNF level and exert an antidepressant effect.

Here, we demonstrated that the methanol extracts of Shiikuwasha (peel, pulp, and seeds) upregulated the BDNF level in the culture medium of ACHN cells. The BDNF-upregulating effects of peel and pulp were almost the same as those of Chinpi (positive control). Furthermore, Shiikuwasha peel and pulp extracts upregulated BDNF level and CREB phosphorylation. Although Shiikuwasha has an anti-obesity effect and other therapeutic properties [40, 41], no study has investigated its effect with respect to upregulating BDNF level and acting as an antidepressant. Our results indicate that Shiikuwasha can be a candidate antidepressant food with a peripheral BDNF-upregulation effect.

Nogata et al. reported that Shiikuwasha contains hesperidin (a type of flavanones) and nobiletin (a type of flavones) [43]. HPLC analysis revealed that hesperidin was rich in the peel and pulp of Shiikuwasha extracts used in this study. Hesperidin reportedly has BDNF-upregulating effects [44] and activates the PKA/CREB/BDNF pathway in vivo [45]. Therefore, hesperidin is likely related to Shiikuwasha peel and pulp-induced BDNF upregulation. HPLC analysis confirmed the presence of nobiletin in peel extracts but not pulp and seed extracts. Nobiletin exerts a BDNF-increasing effect in stressed rats hippocampus [46]. Nobiletin may have partially contributed to the BDNF-increasing effect of Shiikuwasha peel. Hesperidin and nobiletin, which are abundant in Shiikuwasha, reportedly exerted antidepressant effects and attenuated the reduction in hippocampal BDNF level in a mild traumatic brain injury- and chronic mild stress-induced rodent model of depression, respectively [44, 46]. Furthermore, consumption of flavonoids (such as hesperidin, narirutin, and nobiletin)-rich orange juice increases the serum BDNF level in young adults with depressive symptoms [47]. Therefore, Shiikuwasha, a citrus fruit rich in hesperidin and nobiletin, is thought to be beneficial in preventing and treating depression.

The development of therapeutic agents for CNS disorders, such as depression, Alzheimer’s disease, and Parkinson’s disease, has not been as successful as that for peripheral diseases, owing to low permeability of compounds into the brain [48]. Therefore, it is important to find agents that can be clinically used without considering their brain penetration. Here, we demonstrated that Shiikuwasha extracts increased the BDNF level in human renal adenocarcinoma ACHN. Schmidt and Duman reported that subcutaneous BDNF administration (8 µg/day for 14 d) increased the level of BDNF in the mouse hippocampus compared with that in the control [34], suggesting that peripheral BDNF upregulation leads to an increase in brain BDNF level. As our results were from an in vitro analysis, we cannot definitively conclude that Shiikuwasha increases the peripheral BDNF level in vivo. However, we previously demonstrated that red foxtail millet eliciting an approximately 1.4-fold increase in BDNF level in ACHN cells could increase rat serum BDNF level by approximately 1.3-fold [37]; in particular, the BDNF level in the culture medium treated with 100 μg/mL red foxtail millet and control were 250.0 pg/mL and 175.2 pg/mL, respectively. The peel and pulp of Shiikuwasha showed a greater BDNF-upregulating effect than that of red foxtail millet in ACHN cells; therefore, Shiikuwasha can potentially increase BDNF level in vivo. If Shiikuwasha increases the serum BDNF level, then the BDNF level in the brain will increase with the transport of peripheral BDNF through the blood–brain barrier.

The serum BDNF level in healthy individuals is approximately 1.2-fold higher than that in patients with depression [49]. Moreover, even among healthy individuals, the serum BDNF level is lower in individuals with occupational stress than in individuals who are not regularly exposed to stress [50]. Considering that Shiikuwasha peel and pulp extracts elicited an approximately twofold higher effect on ACHN cells, and BDNF is largely synthesized in the kidney [29], Shiikuwasha may be useful as a prophylactic and therapeutic agent against depression. However, the effect of the in vivo treatment of Shiikuwasha on peripheral BDNF level remains unclear. In the future, we plan to investigate whether the administration of Shiikuwasha upregulates BDNF level and induces antidepressant-like effects in a rat model of depression.

Conclusions

We demonstrated the BDNF-upregulating effect of the methanol extracts of Shiikuwasha peel, pulp, and seeds in the culture medium of ACHN cells. Furthermore, we revealed that the extracts of Shiikuwasha peel and pulp upregulate BDNF expression. Hence, our study reports the novel function of Shiikuwasha as potential agent for the prevention and treatment of depression. Further studies are required to identify the active compounds demonstrating BDNF upregulation and to reveal that Shiikuwasha and those active compounds induce antidepressant-like effects in vivo.

Availability of data and materials

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Abbreviations

Akt:

Protein kinase B

BDNF:

Brain-derived neurotrophic factor

cAMP:

Cyclic adenosine monophosphate

cDNA:

Complementary DNA

CNS:

Central nervous system

CREB:

Cyclic adenosine monophosphate response element-binding protein

DMEM:

Dulbecco’s modified Eagle’s medium

DMSO:

Dimethyl sulfoxide

MTT:

3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide

MEK:

Mitogen-activated protein kinase kinase

NARO:

National Agriculture and Food Research Organization

PKA:

Cyclic adenosine monophosphate-dependent protein kinase

qRT-PCR:

Quantitative reverse transcription-polymerase chain reaction

References

  1. O’Keane V, Frodl T, Dinan TG. A review of atypical depression in relation to the course of depression and changes in HPA axis organization. Psychoneuroendocrinology. 2012;37:1589–99.

    PubMed  Google Scholar 

  2. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155–62.

    PubMed  Google Scholar 

  3. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63:699–704.

    CAS  PubMed  Google Scholar 

  4. Covington HE III, Vialou V, Nestler EJ. From synapse to nucleus: Novel targets for treating depression. Neuropharmacology. 2010;58:683–93.

    CAS  PubMed  Google Scholar 

  5. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1:549–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: A dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004;27:589–94.

    CAS  PubMed  Google Scholar 

  7. Zhao H, Alam A, San CY, Eguchi S, Chen Q, Lian Q, et al. Molecular mechanisms of brain-derived neurotrophic factor in neuro-protection: recent developments. Brain Res. 2017;1665:1–21.

    CAS  PubMed  Google Scholar 

  8. Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. CREB: a major mediator of neuronal neurotrophin responses. Neuron. 1997;19:1031–47.

    CAS  PubMed  Google Scholar 

  9. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35:605–23.

    CAS  PubMed  Google Scholar 

  10. Yamamoto KK, Gonzalez GA, Biggs WH III, Montminy MR. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature. 1988;334:494–8.

    CAS  PubMed  Google Scholar 

  11. Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell. 1989;59:675–80.

    CAS  PubMed  Google Scholar 

  12. Liu SH, Lai YL, Chen BL, Yang FY. Ultrasound enhances the expression of brain-derived neurotrophic factor in astrocyte through activation of TrkB-Akt and calcium-CaMK signaling pathways. Cereb Cortex. 2017;27:3152–60.

    PubMed  Google Scholar 

  13. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116–27.

    CAS  PubMed  Google Scholar 

  14. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597–606.

    CAS  PubMed  Google Scholar 

  15. Guilloux JP, Douillard-Guilloux G, Kota R, Wang X, Gardier AM, Martinowich K, et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry. 2012;17:1130–42.

    CAS  PubMed  Google Scholar 

  16. Li S, Wang C, Wang M, Li W, Matsumoto K, Tang Y. Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms. Life Sci. 2007;80:1373–81.

    CAS  PubMed  Google Scholar 

  17. Lee B, Shim I, Lee H, Hahm DH. Fucoidan prevents depression-like behavior in rats exposed to repeated restraint stress. J Nat Med. 2013;67:534–44.

    CAS  PubMed  Google Scholar 

  18. Li YC, Wang LL, Pei YY, Shen JD, Li HB, Wang BY, et al. Baicalin decreases SGK1 expression in the hippocampus and reverses depressive-like behaviors induced by corticosterone. Neuroscience. 2015;311:130–7.

    CAS  PubMed  Google Scholar 

  19. Thakare VN, Aswar MK, Kulkarni YP, Patil RR, Patel BM. Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response. Physiol Behav. 2017;179:401–10.

    CAS  PubMed  Google Scholar 

  20. Cao K, Shen C, Yuan Y, Bai S, Yang L, Guo L, et al. SiNiSan ameliorates the depression-like behavior of rats that experienced maternal separation through 5-HT1A receptor/CREB/BDNF pathway. Front Psychiatry. 2019;10:160.

    PubMed  PubMed Central  Google Scholar 

  21. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22:3251–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005;1037:204–8.

    CAS  PubMed  Google Scholar 

  23. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J. 1990;9:2459–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Yan Q, Rosenfeld RD, Matheson CR, Hawkins N, Lopez OT, Bennett L, et al. Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience. 1997;78:431–48.

    CAS  PubMed  Google Scholar 

  25. Matthews VB, Åström MB, Chan MH, Bruce CR, Krabbe KS, Prelovsek O, et al. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia. 2009;52:1409–18.

    CAS  PubMed  Google Scholar 

  26. Ernfors P, Wetmore C, Olson L, Persson H. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. Neuron. 1990;5:511–26.

    CAS  PubMed  Google Scholar 

  27. Maisonpierre PC, Le Beau MM, Espinosa R III, Ip NY, Belluscio L, de la Monte SM, et al. Human and rat brain-derived neurotrophic factor and Neurotrophin-3: Gene structures, distributions, and chromosomal localizations. Genomics. 1991;10:558–68.

    CAS  PubMed  Google Scholar 

  28. Katoh-Semba R, Takeuchi IK, Semba R, Kato K. Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. J Neurochem. 1997;69:34–42.

    CAS  PubMed  Google Scholar 

  29. Lommatzsch M, Braun A, Mannsfeldt A, Botchkarev VA, Botchkareva NV, Paus R, et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived neurotrophic functions. Am J Pathol. 1999;155:1183–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Endlich N, Lange T, Kuhn J, Klemm P, Kotb AM, Siegerist F, et al. BDNF: mRNA expression in urine cells of patients with chronic kidney disease and its role in kidney function. J Cell Mol Med. 2018;22:5265–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology. 1998;37:1553–61.

    CAS  PubMed  Google Scholar 

  32. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry. 2009;42:270–6.

    CAS  PubMed  Google Scholar 

  33. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14:347–53.

    CAS  PubMed  Google Scholar 

  34. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology. 2010;35:2378–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Nakajima K, Oiso S, Kariyazono H. Brain-derived neurotrophic factor up-regulation by the methanol extract of foxtail millet in human peripheral cells. J Nutr Sci Vitaminol. 2020;66:284–8.

    CAS  PubMed  Google Scholar 

  36. Nakajima K, Okubo S, Oiso S. Identification of traditional Japanese Kampo medicines and crude drugs that upregulate brain derived neurotrophic factor in human peripheral cells. Acta Neurobiol Exp. 2021;81:393–404.

    Google Scholar 

  37. Nakajima K, Tomohiro H, Oiso S. Red foxtail millet upregulates brain-derived neurotrophic factor levels in vitro and in vivo. Biomed Res. 2023;44:97–104.

    CAS  PubMed  Google Scholar 

  38. Nakajima K, Okubo S, Oiso S. Increasing effect of Citrus natsudaidai on brain-derived neurotrophic factor. J Oleo Sci. 2023;72:245–55.

    CAS  PubMed  Google Scholar 

  39. Asikin Y, Kawahira S, Goki M, Hirose N, Kyoda S, Wada K. Extended aroma extract dilution analysis profile of shiikuwasha (Citrus depressa Hayata) pulp essential oil. J Food Drug Anal. 2018;26:268–76.

    CAS  PubMed  Google Scholar 

  40. Sakata Y, Okamoto T, Oshio K, Nakamura H, Iwamoto H, Namba K, et al. Dietary supplementation with shiikuwasha extract attenuates dexamethasone-induced skeletal muscle atrophy in aged rats. Springerplus. 2016;5:816.

    PubMed  PubMed Central  Google Scholar 

  41. Yen YW, Lai YJ, Kong ZL. Dietary supplements of shiikuwasha extract attenuates osteoarthritis progression in meniscal/ligamentous injury and obese rats. Nutrients. 2019;11:1312.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Uto T, Morinaga O, Tanaka H, Shoyama Y. Analysis of the synergistic effect of glycyrrhizin and other constituents in licorice extract on lipopolysaccharide-induced nitric oxide production using knock-out extract. Biochem Biophys Res Commun. 2012;417:473–8.

    CAS  PubMed  Google Scholar 

  43. Nogata Y, Sakamoto K, Shiratsuchi H, Ishii T, Yano M, Ohta H. Flavonoid composition of fruit tissues of Citrus species. Biosci Biotechnol Biochem. 2006;70:178–92.

    CAS  PubMed  Google Scholar 

  44. Kosari-Nasab M, Shokouhi G, Ghorbanihaghjo A, Abbasi MM, Salari AA. Hesperidin attenuates depression-related symptoms in mice with mild traumatic brain injury. Life Sci. 2018;213:198–205.

    CAS  PubMed  Google Scholar 

  45. Zhu X, Liu H, Deng Z, Yan C, Liu Y, Yin X. Hesperidin exerts anxiolytic-like effects in rats with streptozotocin-induced diabetes via PKA/CREB signaling. Curr Mol Pharmacol. 2023;16:91–100.

    CAS  PubMed  Google Scholar 

  46. Li J, Zhou Y, Liu BB, Liu Q, Geng D, Weng LJ, et al. Nobiletin ameliorates the deficits in hippocampal BDNF, TrkB, and synapsin I induced by chronic unpredictable mild stress. Evid Based Complement Alternat Med. 2013;2013: 359682.

    PubMed  PubMed Central  Google Scholar 

  47. Park M, Choi J, Lee HJ. Flavonoid-rich orange juice intake and altered gut microbiome in young adults with depressive symptom: A randomized controlled study. Nutrients. 2020;12:1815.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood–brain barrier, and central nervous system drug discovery. NeuroRx. 2005;2:554–71.

    PubMed  PubMed Central  Google Scholar 

  49. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109:143–8.

    CAS  PubMed  Google Scholar 

  50. Mitoma M, Yoshimura R, Sugita A, Umene W, Hori H, Nakano H, et al. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress? Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:679–85.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Shiikuwasha was kindly provided by the Division of Citrus Research, Institute of Fruit Tree and Tea Science, National Agriculture and Food Research Organization (Shizuoka, Japan).

Funding

This work was partially supported by the Japan Society for the Promotion of Science KAKENHI under Grant (number 19K20134 and 22K11843), the Association for Health Economics Research and Social Insurance and Welfare (Tokyo, Japan), the Bank of Okinawa (Okigin Furusato Shinko Kikin), and the Toyo Suisan Foundation (Tokyo, Japan).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki, 859-3298, Japan

    Kensuke Nakajima, Shinya Okubo, Tomoe Ohta, Takuhiro Uto & Shigeru Oiso

  2. Graduate School of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki, 859-3298, Japan

    Shinya Okubo, Tomoe Ohta, Takuhiro Uto & Shigeru Oiso

Authors
  1. Kensuke Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinya Okubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomoe Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuhiro Uto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigeru Oiso
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KN conceived and designed the experiments. KN, SOk, TO, and TU performed the experiments. KN, SOk, TO, TU, and SOi analyzed the data. KN, SOk, TO, TU, and SOi wrote the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shigeru Oiso.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakajima, K., Okubo, S., Ohta, T. et al. Upregulation of brain-derived neurotrophic factor by Shiikuwasha (Citrus depressa Hayata). J Pharm Health Care Sci 9, 40 (2023). https://doi.org/10.1186/s40780-023-00309-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40780-023-00309-7

Keywords

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us